Accéder au contenu
Merck

Hepatitis E virus epidemiology among HIV-infected women in an urban area in Tanzania.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2018-05-29)
Lene H Harritshøj, Zahra P Theilgaard, Ebba Mannheimer, Sofie E Midgley, Mercy Chiduo, Henrik Ullum, Terese L Katzenstein
RÉSUMÉ

This study was performed to determine the seroprevalence and incidence of hepatitis E virus (HEV) infection among HIV-infected women during pregnancy and after delivery in a cohort of 200 Tanzanian women. HIV-infected women participating in a study on antiretroviral therapy for the prevention of mother-to-child HIV transmission between 2006 and 2011, were tested retrospectively for anti-HEV immunoglobulin G (IgG) in plasma samples at 9 months post-partum. Anti-HEV IgG-positive patients were tested for anti-HEV IgG and immunoglobulin M (IgM) in samples from enrolment, and seroconverting women were tested for HEV RNA. A total of 16 women were anti-HEV IgG-positive, two of whom had seroconverted between enrolment and 9 months post-partum, with no detection of anti-HEV IgM or HEV RNA, yielding an HEV seroprevalence of 8.0% (confidence interval 5.0-12.6%) and an annual incidence rate of 1.0% (confidence interval 0.2-3.4%). CD4 cell counts were relatively high (median 403×106/l), with no significant difference between women with and without serological signs of HEV. An annual HEV infection incidence rate of 1% strongly indicates ongoing transmission of HEV in Tanzania and should be kept in mind for pregnant women presenting with signs of acute hepatitis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Mouse IgM ELISA Kit